Day Three Labs to Study Cannabis as a Treatment for Parkinson’s Disease
Day Three Labs (DTL), is a Colorado-based cannabinoid CPG ingredient manufacturer. With their expertise in the development of these novel cannabis products, the company has set out to evaluate cannabis as a treatment for Parkinson’s Disease.
This mission has come to light after the company announced the world’s first government-sponsored cannabis technology incubator will aid in funding this research.
While the headquarters are in Denver, the research facility is in Israel, where regulations make studying cannabis much easier than in the United States. They are the only company to have passed the first phase of the CanNegev program, a cannabis technology incubator that receives funding from the Israeli government.
With this first phase complete, the company will receive funding and move into phase two. This means initiating the research and data collection for presentation to the Israel Innovation Authority as soon as September.
Through the research program, Day Three Labs plans to study cannabis compounds delivered via its proprietary Unlokt technology as a treatment for Parkinson’s disease symptoms. The funding from CanNegev will enable the company to find the combination of cannabinoids that work best to treat Parkinson’s disease and allow the company to carry the research from the lab to product development.
Parkinson’s Disease affects more than 10 million worldwide. Cannabis has been an approved treatment option in Germany since 2017. However, with the ever growing list of marijuana and cannabis strains and product types, choosing a formulation that is most effective at providing consistent relief is a true challenge. DTL’s research will take advantage of the Unlokt technology which packs cannabis into a natural protein which bypasses the liver, shuttling cannabis directly into the body’s circulation. This allows the cannabinoids and terpenes to be released and absorbed into the bloodstream and should have a beneficial effect.
“Unlokt is a significant leap in technology that will disrupt traditional research and delivery of cannabinoid compounds and beyond,” said Josh Rubin, co-founder and CEO of Day Three Labs. “Utilizing a groundbreaking technology like Unlokt in the adult-use market is revolutionary and game-changing, and creates incredibly enjoyable products, but it only scratches the surface of what this technology is capable of. Our work with CanNegev is just the beginning of the technological advances we are bringing to this fast-growing industry with the hope of eradicating previously untreatable illnesses and conditions and bringing solutions to the cannabis industry that are safer, more efficacious and efficient.”
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
